Last reviewed · How we verify

NCT06644274

The Value of 68Ga-grazytracer PET in Monitoring Responses to Immunotherapy of Gastrointestinal Malignancies

Recruiting now Last updated 11 December 2024
What this trial tests

trial in Gastrointestinal Malignancies in 40 participants. Currently enrolling.

Timeline
20 October 2024
Primary endpoint
30 June 2026
31 July 2027

Quick facts

Lead sponsorRuijin Hospital
StatusRecruiting now
Study typeOBSERVATIONAL
Enrollment40
Start date20 October 2024
Primary completion30 June 2026
Estimated completion31 July 2027
Sites1 location across China

Conditions studied

Sponsor

Ruijin Hospital

Who can join

Adults 18 to 75, any sex, with Gastrointestinal Malignancies. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to investigate the value of 68Ga-grazytracer in predicting the efficacy of immunotherapy for gastrointestinal malignancies.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Ruijin Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06644274.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing